Analysts Set Alphatec Holdings, Inc. (NASDAQ:ATEC) Price Target at $17.40

Alphatec Holdings, Inc. (NASDAQ:ATEC) has earned a consensus recommendation of “Moderate Buy” from the fifteen analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $17.40.

Several research analysts recently weighed in on ATEC shares. TD Cowen increased their target price on Alphatec from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Stifel Nicolaus lowered their price target on Alphatec from $16.00 to $13.00 and set a “buy” rating for the company in a research report on Wednesday, July 8th. BMO Capital Markets upped their price target on Alphatec from $11.00 to $12.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. UBS Group raised their price objective on Alphatec from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alphatec in a research note on Monday, August 3rd.

Insider Buying and Selling

In other Alphatec news, General Counsel Tyson Marshall sold 8,168 shares of Alphatec stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total transaction of $78,821.20. Following the transaction, the general counsel directly owned 630,398 shares of the company’s stock, valued at $6,083,340.70. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Patrick Miles acquired 115,000 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were acquired at an average price of $8.81 per share, with a total value of $1,013,150.00. Following the completion of the purchase, the chief executive officer owned 5,893,551 shares of the company’s stock, valued at $51,922,184.31. This trade represents a 1.99% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 13.48% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Alphatec

A number of hedge funds have recently made changes to their positions in ATEC. Next Century Growth Investors LLC boosted its position in Alphatec by 6.1% during the 4th quarter. Next Century Growth Investors LLC now owns 2,418,298 shares of the medical technology company’s stock worth $50,881,000 after purchasing an additional 138,915 shares during the period. Bank of America Corp DE raised its position in Alphatec by 26.9% in the first quarter. Bank of America Corp DE now owns 2,560,971 shares of the medical technology company’s stock valued at $27,863,000 after purchasing an additional 543,059 shares during the period. Emerald Advisers LLC raised its position in Alphatec by 10.4% in the first quarter. Emerald Advisers LLC now owns 1,807,307 shares of the medical technology company’s stock valued at $19,664,000 after purchasing an additional 169,578 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Alphatec by 11.3% during the fourth quarter. BNP Paribas Financial Markets now owns 708,548 shares of the medical technology company’s stock worth $14,908,000 after purchasing an additional 71,933 shares in the last quarter. Finally, Granite Investment Partners LLC lifted its stake in shares of Alphatec by 4.7% during the first quarter. Granite Investment Partners LLC now owns 1,195,156 shares of the medical technology company’s stock worth $13,003,000 after purchasing an additional 54,043 shares in the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Price Performance

Alphatec stock opened at $10.28 on Tuesday. Alphatec has a 1 year low of $6.82 and a 1 year high of $23.29. The company has a debt-to-equity ratio of 40.35, a quick ratio of 1.07 and a current ratio of 1.89. The firm has a 50 day moving average price of $9.40 and a 200 day moving average price of $9.69. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -14.48 and a beta of 0.85.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Tuesday, August 4th. The medical technology company reported $0.07 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.07. Alphatec had a negative net margin of 13.49% and a negative return on equity of 6,752.24%. The company had revenue of $213.51 million for the quarter, compared to the consensus estimate of $211.26 million. During the same quarter last year, the firm posted $0.02 earnings per share. Alphatec’s revenue was up 15.1% on a year-over-year basis. Sell-side analysts predict that Alphatec will post -0.45 earnings per share for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on improving the surgical treatment of spinal disorders. The company develops and commercializes products designed to support spine surgery, including implants, biologics, surgical instruments and related technologies.

Its portfolio is intended for procedures addressing conditions such as spinal deformities, degenerative disc disease and other disorders affecting the spine. Alphatec emphasizes surgeon-focused solutions and integrated technologies that support preoperative planning, intraoperative decision-making and the placement of spinal implants.

Headquartered in Carlsbad, California, Alphatec serves hospitals, surgeons and other healthcare providers in the United States and select international markets.